Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
US Department of Justice
Daiichi Sankyo
QuintilesIMS
Healthtrust
Citi
Baxter
Queensland Health
Fuji

Generated: April 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,492,416

« Back to Dashboard

Summary for Patent: 8,492,416
Title:2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
Abstract: The invention concerns 2-oxo-1-pyrrolidine derivatives of formula I, ##STR00001## wherein the substituents are as defined in the specification, as well as their use as pharmaceuticals. The compounds of the invention are particularly suited for treating neurological disorders such as epilepsy.
Inventor(s): Kenda; Beno t (Emines, BE), Pasau; Patrick (Chastre, BE), Lallemand; Benedicte (Namur, BE)
Assignee: UCB Pharma, S.A. (Brussels, BE)
Application Number:13/222,477
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,492,416

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Ucb Inc BRIVIACT brivaracetam SOLUTION;INTRAVENOUS 205837-001 May 12, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF PARTIAL-ONSET SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY ➤ Sign Up
Ucb Inc BRIVIACT brivaracetam SOLUTION;INTRAVENOUS 205837-001 May 12, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF PARTIAL ONSET SEIZURES IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY ➤ Sign Up
Ucb Inc BRIVIACT brivaracetam SOLUTION;ORAL 205838-001 May 12, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF PARTIAL-ONSET SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY ➤ Sign Up
Ucb Inc BRIVIACT brivaracetam SOLUTION;ORAL 205838-001 May 12, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF PARTIAL ONSET SEIZURES IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,492,416

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0004297.8Feb 23, 2000

Non-Orange Book US Patents Family Members for Patent 8,492,416

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,806,287 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses ➤ Sign Up
6,858,740 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses ➤ Sign Up
6,911,461 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses ➤ Sign Up
6,713,635 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Fuji
Queensland Health
Citi
Boehringer Ingelheim
Accenture
Chinese Patent Office
Cipla
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.